The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells

Chemotherapy

Volumn 58, Issue 4, 2012, Pages 273-281

  Zheng, Jie ^a   Zou, Xianjin ^a   Yao, Jia ^a  

^a First People's Hospital of Jingmen   (China)

Author keywords

Breast cancer cell line proliferation; Breast cancer therapy; GDC 0941; Rapamycin

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROGESTERONE RECEPTOR; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CELL STRAIN SK BR 3; CELL STRAIN T 47D; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DOWN-REGULATION; FEMALE; HUMANS; INDAZOLES; MCF-7 CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; SULFONAMIDES; TOR SERINE-THREONINE KINASES;

EID: 84866522619     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000341812     Document Type: Article

References (35)

1. Bader AG, Kang S, Zhao L, Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005; 5: 921-929.
2. Weycker D, Edelsberg J, Kartashov A, Barron R, Lyman G: Chemotherapy 2012; 58: 8-18.
3. Yu K, Toral-Barza L, Shi C, Zhang WG and Zask A: Response and determinants of cancer cell susceptibility to PI3K inhibitors. Cancer Biol Ther 2008; 7: 307-315.
4. Bjornsti MA, Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335-348.
5. Sawyers CL: Will mTOR inhibitors make it as cancer drugs? Cancer Cell 2003; 4: 343-348.
6. Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945.
7. Lopiccolo J, Blumenthal GM, Bernstein WB, Dennis PA: Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11: 32-50.
8. Liu TJ, Koul D, LaFortune T, et al: NVPBEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 2009; 8: 2204-2210.
9. Schultz RM, Merriman RL, Andis SL, et al: In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res 1995; 15: 1135-1139.
10. Norman BH, Shih C, Toth JE, et al: Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. J Med Chem 1996; 39: 1106-1111.
11. Vlahos CJ, Matter WF, Hui KY, Brown RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269: 5241-5248.
12. Folkes AJ, Ahmadi K, Alderton WK, et al: The identification of 2-(1Hindazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-ylthie-no [3, 2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008; 51: 5522-5532.
13. Sun SY, Rosenberg LM, Wang X, et al: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65: 7052-7058.
14. Easton JB, Houghton PJ: mTOR and cancer therapy. Oncogene 2006; 25: 6436-6446.
15. Faivre S, Kroemer G, Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5: 671-688.
16. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ: Rapamycin induces feedback activation of Akt signaling through an IGF-1Rdependent mechanism. Oncogene 2007; 26: 1932-1940.
17. Witzig TE, Geyer SM, Ghobrial I, et al: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347-5356.
18. Edgar KA, Wallin JJ, Berry M, et al: Isoformspecific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Res 2010; 70: 1164-1172.
19. Arkaitz C, Li M, Julie TF, et al: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065-3074.
20. Liu H, Zang C, Emde A, et al: Anti-tumor effect of honokiol alone and incombination with other anti-cancer agents in breast cancer. Eur J Pharmacol 2008; 591: 43-45.
21. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143-163.
22. Butt AJ, Firth SM, Baxter RC: The IGF axis and programmed cell death. Immunol Cell Biol 1999; 77: 256-262.
23. Oh YI, Kim JH, Kang CW: Involvement of insulin-like growth factor-I secretion and all-trans-retinoic acid-induced decrement in viability in MCF-7 cells. Chemotherapy 2011; 5: 17-26
24. Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-500.
25. Di Cristofano A, Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-390.
26. Hoadley KA, Weigman VJ, Fan C, et al: EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007; 8: 258.
27. Crew CM, Alessandrini A, Erikson RL: ERKs: their fifteen minites has arrived. Cell Growth Differ 1992; 3: 135-142.
28. Hidalgo M, Rowinsky EK: The rapamycinsensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 9: 6680-6686.
29. Mills, GB, Lu Y, Kohn EC: Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci 2001; 98: 10031-10033.
30. Minniti CP, Luan D, O'Grady C, Rosenfeld RG, Oh Y, Helman LJ: Insulin-like growth factor II over-expression in myoblasts induces phenotypic changes typical of the malignant phenotype. Cell Growth Differ 1995; 6: 263-269.
31. Wan X, Helman LJ: Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-IIoverexpressing rhabdomyosarcomas cells. Oncogene 2003; 22: 8205-8211.
32. Radimerski T, Montagne J, Hemmings-Mieszczak M, Thomas G: Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. Genes Dev 2002; 16: 2627-2632.
33. Harrington LS, Findlay GM, Gray A, et al: The TSC1-2 tumor suppressor control insulin-PI3K signaling via regulation of IRS protein. J Cell Biol 2004; 166: 213-222.
34. Manning BD: Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004; 167: 399-403.
35. Gottschalk AR, Basila D, Wong M, et al: p27Kip1 is required for PTEN-induced G1 growth arrest. Cancer Res 2001; 61: 2105-2111.